Conference News

Migaldendranib May Move the Needle in AMD, DME

Michael A. Singer, MD, shares early phase 2 data supporting D-4517.2 as a safe and effective subcutaneous therapy, reducing injection burden and preserving vision.

Share

  • 1

    The Retina World Congress discusses advancements and challenges in retina specialties.

  • 2

    The event aims to improve patient care through collaboration and innovation.

  • 3

    It provides a platform for education and knowledge dissemination.

  • 4

    Experts gather to share cutting-edge research and best practices.

  • 5

    The Congress focuses on enhancing outcomes and patient care in retina specialties.

Original Source(s)

Migaldendranib May Move the Needle in AMD, DME

Michael A. Singer, MD, shares early phase 2 data supporting D-4517.2 as a safe and effective subcutaneous therapy, reducing injection burden and preserving vision.

  • by Michael A. Singer, MD

  • May 1, 2025

  • 5 min

Related Content

Understanding Protocol AO, the DRCR Retina Network’s Study of Home OCT

A conversation with Christina Y. Weng, MD, MBA

PRISM Trial Update Presented at RWC

Mark Barakat, MD, provided an update on the PRISM clinical trial for 4D-150 (4DMT) for wet AMD at the Retina World Congress meeting in Fort Lauderdale.

Real-World nAMD Treatment Patterns Reveal Cost of Switching

Analysis of Medicare claims show increases in drug-related expenditures after initial low-cost therapy.